The U.S. intravenous immunoglobulin (IVIG) market was valued at USD 5.74 billion in 2022 and is projected to expand at a 7.7% CAGR from 2023 to 2030. Growth is being supported by increasing demand for immunoglobulin replacement therapy among patients with Primary Immunodeficiency Diseases (PIDD), along with the approval of new IVIG products that are broadening available treatment options. What...